Abstract: The invention relates to anti-EGF like domain multiple 6 antibody (anti-EGFL6 antibody) and cancer detection (or diagnosis) and treatment using the anti-EGFL6 antibody. The present invention creates anti-EGFL6 antibodies, particularly, a single-chain antibody fragments (scFv) and humanized antibody, which have ability in binding to EGFL6 and in inhibiting angiogenesis and cancer cell growth.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
February 14, 2023
Assignees:
Taipei Medical University, Changhua Christian Medical Foundation Changhua Christian Hospital, National Research institute of Chinese Medicine, Ministry of Health and Welfare
Abstract: The invention relates to compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, the invention provides chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.
Type:
Grant
Filed:
March 22, 2018
Date of Patent:
June 21, 2022
Assignees:
TAIPEI MEDICAL UNIVERSITY, NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE, MINISTRY OF HEALTH AND WELFARE, ACADEMIA SINICA, BUDDHIST TZU CHI MEDICAL FOUNDATION
Inventors:
Heng Lin, Ming-jaw Don, Ching-feng Cheng, Jing-jy Cheng, Wen-shan Li, Hui-chen Ku, Hsiao-fen Li, Hsi-hsien Chen, W J Huang
Abstract: A composition of plant ingredients, a herbal composition for inhibiting coronavirus and cytokine storm, and a preparation method of the herbal composition are introduced. The composition of plant ingredients has Heartleaf Houttuynia, Indigowoad Root, Fineleaf Nepeta, Saposhnikovia Root, Mulberry Leaf, Scutellaria Root, Mongolian Snakegourd Fruit, Magnolia Bark, Peppermint Herb and Baked Liquorice Root. The herbal composition has 1 to 20 parts by weight of Heartleaf Houttuynia, Indigowoad Root, Fineleaf Nepeta, Saposhnikovia Root, Mulberry Leaf, Scutellaria Root, Mongolian Snakegourd Fruit, Magnolia Bark, Peppermint Herb and Baked Liquorice Root.
Type:
Grant
Filed:
December 21, 2020
Date of Patent:
May 17, 2022
Assignee:
NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE, MINISTRY OF HEALTH AND WELFARE
Abstract: Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.
Type:
Grant
Filed:
April 12, 2017
Date of Patent:
April 30, 2019
Assignee:
NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE, MINISTRY OF HEALTH AND WELFARE